Search alternatives:
significantly increased » significant increase (Expand Search)
significant decrease » significant increase (Expand Search)
significant 17 » significant _ (Expand Search), significant co (Expand Search), significant gap (Expand Search)
17 decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 701 - 720 results of 21,342 for search '(( significant 17 decrease ) OR ( ((significant decrease) OR (significantly increased)) decrease ))', query time: 0.66s Refine Results
  1. 701
    Changes in alpha diversity in the weeks before anti-TNF-a treatment.

    Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 702
    Family clades associating with week to treatment, symptom score or FC.

    Family clades associating with week to treatment, symptom score or FC. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 703
    Alpha diversity measures across all 727 samples.

    Alpha diversity measures across all 727 samples. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 704
    Summary statistics for analysis of single genera clades.

    Summary statistics for analysis of single genera clades. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 705
    Abundance of the top 20 most abundant genera in one patient (Patient 1), across the weeks running up to treatment.

    Abundance of the top 20 most abundant genera in one patient (Patient 1), across the weeks running up to treatment. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 706
    Development of alpha diversity across weeks towards a new TNF treatment for each IBD disease subtype.

    Development of alpha diversity across weeks towards a new TNF treatment for each IBD disease subtype. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 707
    Community composition of samples from five individuals show clustering of samples according to individual.

    Community composition of samples from five individuals show clustering of samples according to individual. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 708
    Study taxonomy.

    Study taxonomy. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 709
    Microbiome profile of the most abundant phyla in one patient (Patient 1), across 12 infliximab treatments (-1 is the week before treatment, -2 the two weeks before treatment, etc).

    Microbiome profile of the most abundant phyla in one patient (Patient 1), across 12 infliximab treatments (-1 is the week before treatment, -2 the two weeks before treatment, etc). by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 710
    S5 Fig -

    S5 Fig - by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 711
    Summary statistics for analysis of single family clades.

    Summary statistics for analysis of single family clades. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 712
    STORMS microbiome reporting checklist.

    STORMS microbiome reporting checklist. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 713
    Post-hoc analysis for visit-wise differences in dual-task learning. Significant differences between visits are indicated with an asterisk (*).

    Post-hoc analysis for visit-wise differences in dual-task learning. Significant differences between visits are indicated with an asterisk (*). by Swati M. Surkar (8399427)

    Published 2025
    Save to List
    Saved in:
  14. 714
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 715
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 716
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 717
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 718
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 719
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 720
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: